Xtant Medical Hldgs Q1 2024 GAAP EPS $(0.03) Misses $(0.01) Estimate, Sales $27.873M Beat $25.750M Estimate
Portfolio Pulse from Benzinga Newsdesk
Xtant Medical Holdings (AMEX:XTNT) reported Q1 2024 GAAP EPS of $(0.03), missing the $(0.01) estimate by 200%. However, sales of $27.873M beat the $25.750M estimate by 8.24%, marking a 55.34% increase from the same period last year.
May 15, 2024 | 8:36 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Xtant Medical Holdings reported mixed Q1 2024 results with a GAAP EPS of $(0.03), missing estimates by 200%, but sales of $27.873M beat estimates by 8.24%. The sales growth of 55.34% YoY is a positive sign.
The mixed results, with a significant EPS miss but strong sales growth, suggest a neutral short-term impact on XTNT's stock price. Investors may weigh the negative EPS against the positive sales performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100